Previously, AML risk classification related to FLT3-ITD was dependent on allelic ratio and NPM1 mutational status [11], but as of 2022, all FLT3-ITD disease is considered intermediate risk [4]. This evidence concerns the gene FLT3 and acute myeloid leukemia.